Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 7/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | BMX | P51813 | 2/20 | 0.33 |
| ▸ | ITK | Q08881 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29333457 | 1.00 | BTK (0.37) | BTKCCNCCDK8GPR84RORC | |
| SCHEMBL29333472 | 0.88 | CCNC (0.38) | BTKCCNCCDK8EGFRBMX | |
| SCHEMBL31008591 | 0.85 | BTK (0.38) | BTKCCNCCDK8ERN1 | |
| SCHEMBL29333474 | 0.85 | BTK (0.38) | BTKCCNCCDK8ERN1 | |
| SCHEMBL31008535 | 0.85 | CECR2 (0.35) | BTKCCNCCDK8GPR84RORC | |
| SCHEMBL29333475 | 0.85 | CECR2 (0.35) | BTKCCNCCDK8GPR84RORC | |
| SCHEMBL29333435 | 0.84 | BTK (0.41) | BTKGPR84RORCHCRTR1HCRTR2 | |
| SCHEMBL31008551 | 0.84 | BTK (0.41) | BTKGPR84RORCHCRTR1HCRTR2 | |
| SCHEMBL31008730 | 0.84 | BTK (0.41) | BTKALOX5APFEN1 | |
| SCHEMBL29333477 | 0.84 | BTK (0.41) | BTKALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | BTK 3290/4885CCNC 4349/4885CDK8 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.